Lionco(SH:603669) Shang Hai Zheng Quan Bao·2025-10-29 22:37Core Viewpoint - Lingkang Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, Hainan Lingkang Pharmaceutical Co., Ltd., has been shortlisted for the 11th batch of national drug centralized procurement for its product, injectable cefoperazone sodium, which is expected to positively impact the company's market expansion and brand influence [1][3]. Group 1: Drug Procurement Announcement - The injectable cefoperazone sodium is proposed to be selected in the national centralized procurement process, with the final selection subject to confirmation by the procurement office [1]. - The procurement cycle for the selected product is set for three years, starting from the execution date in 2026 until December 31, 2028 [2]. Group 2: Financial Impact - The projected sales revenue for injectable cefoperazone sodium in 2024 is approximately 23.01 million yuan, accounting for 6.06% of the company's total revenue for that year [3]. - For the first half of 2025, the sales revenue is estimated at 1.82 million yuan, representing 1.06% of the company's revenue for that period [3]. - The price of the selected product is expected to decrease compared to current sales prices in the provinces, which may enhance market penetration and brand recognition for the company [3].